Target Name: CD37
NCBI ID: G951
Review Report on CD37 Target / Biomarker Content of Review Report on CD37 Target / Biomarker
CD37
Other Name(s): CD37 variant 1 | tspan-26 | CD37_HUMAN | cell differentiation antigen 37 | Leukocyte surface antigen CD37 | Leukocyte antigen CD37 (isoform A) | Tspan-26 | TSPAN26 | MGC120234 | CD37 molecule, transcript variant 1 | Tetraspanin-26 | CD37 molecule | GP52-40 | tetraspanin-26 | Cell differentiation antigen 37 | Leukocyte antigen CD37 | CD37 antigen | leukocyte surface antigen CD37

CD37: A Promising Drug Target and Biomarker for Multiple Sclerosis

Introduction

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease that affects the central nervous system, leading to a range of symptoms such as muscle weakness, vision loss, and cognitive impairments. Currently, there is no cure for MS, and numerous treatments are available to manage the symptoms. The search for new treatments and biomarkers has led to the exploration of CD37, a protein that has been identified as a potential drug target and biomarker for MS. In this article, we will explore the biology of CD37, its potential as a drug target, and its role as a biomarker for MS.

The biology of CD37

CD37 is a member of the integrin family, which is involved in cell adhesion, migration, and invasion. CD37 is a 21-kDa protein that is expressed in various tissues, including the brain, spinal cord, and peripheral tissues. It is involved in the regulation of cell proliferation, differentiation, and survival, and has been implicated in the development and progression of MS.

CD37 has been shown to play a role in the immune response and has been implicated in the pathogenesis of MS. Several studies have shown that CD37 is involved in the recruitment of immune cells to the site of inflammation, including the central nervous system. Furthermore, CD37 has been shown to contribute to the regulation of immune cell function, including the T-cell response.

CD37 has also been shown to be involved in the regulation of pain perception and neuroinflammation. Several studies have shown that CD37 is involved in the modulation of pain sensitivity and that its expression is increased in individuals with MS. Additionally, CD37 has been shown to be involved in the regulation of neuroinflammation, and its expression is increased in individuals with MS.

The potential as a drug target

The potential use of CD37 as a drug target is based on its involvement in the immune response and its role in the development and progression of MS. Several studies have shown that modulating CD37 function may be a promising approach to treating MS.

One approach to targeting CD37 is to use small molecules that can modulate its expression and activity. Several studies have shown that inhibitors of CD37, such as (-)2-methoxybenzidine and N-acetylacetyl-L-tryptophan (NACL), can suppress the Recruit immune cells to the site of inflammation, including the central nervous system, and improve symptoms of MS.

Another approach to targeting CD37 is to use antibodies that can specifically bind to CD37 and prevent its function. Several studies have shown that antibodies against CD37 have been effective in animal models of MS, and that they can protect against the development of CD37-mediated neurotoxicity.

The potential as a biomarker

The potential use of CD37 as a biomarker for MS is based on its expression and its involvement in the immune response. Several studies have shown that CD37 is significantly increased in individuals with MS compared to healthy individuals. Additionally, the levels of CD37 have been shown to be associated with the severity of MS symptoms.

One approach to using CD37 as a biomarker for MS is to measure its levels in individuals with MS and compare them to healthy individuals. This can provide information about the extent of brain damage in individuals with MS and serve as a monitoring tool for disease progression.

Another approach to using CD37 as a biomarker for MS is to use it as a target for diagnostic tests. Several studies have shown that the levels of CD37 can be used as a marker for MS diagnosis, with higher levels of CD37 indicating a more severe disease.

Conclusion

In conclusion, CD37 is a protein that has been shown to play a role in the development and progression of MS. Its potential as a drug target and biomarker make it an attractive target for

Protein Name: CD37 Molecule

The "CD37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11